| Identification | Back Directory | [Name]
MK-5582 | [CAS]
1254730-81-8 | [Synonyms]
MK-5582
SSTR5 antagonist 2
SSTR5 antagonist 2,SSTR-5 antagonist 2
4-{8-[(2,6-diethoxy-4'-fluorobiphenyI-4-yl)Methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid
Benzoic acid, 4-[8-[(2,6-diethoxy-4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl]-
4-(8-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)Methyl)-3-oxo-2,8-diazaspiro[4.5]decan-2-yl)benzoic acid | [Molecular Formula]
C32H35FN2O5 | [MDL Number]
MFCD18633148 | [MOL File]
1254730-81-8.mol | [Molecular Weight]
546.63 |
| Hazard Information | Back Directory | [Uses]
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM)[1]. | [in vivo]
SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg[1].
SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors[1]. | Animal Model: | Rodent diabetic model without risk of hypoglycemia[1]. | | Dosage: | 10 mg/kg. | | Administration: | Orally. | | Result: | Increased both total and active circulating incretin hormone GLP1 levels. |
| [References]
[1] Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087. DOI:10.1021/acsmedchemlett.8b00305 |
|
|